TY - JOUR
T1 - The prevalence of current smokers and alcohol drinkers among cancer survivors and subjects with no history of cancer among participants in a community-based cardiometabolic screening program in Miyagi prefecture, Japan
T2 - a comparison with nationally representative surveys in other countries
AU - Nishimoto, Yuka
AU - Tsubono, Yoshitaka
AU - Kogure, Mana
AU - Nakamura, Tomohiro
AU - Itabashi, Fumi
AU - Tsuchiya, Naho
AU - Nakaya, Naoki
AU - Tanno, Kozo
AU - Sugawara, Junichi
AU - Kuriyama, Shinichi
AU - Kure, Shigeo
AU - Tsuji, Ichiro
AU - Hozawa, Atsushi
N1 - Funding Information:
The Tohoku Medical Megabank is supported by grants from the Reconstruction Agency, from the Ministry of Education, Culture, Sports, Science, and Technology, and from the Japan Agency for Medical Research and Development. (JP20km0105001).
Funding Information:
The Tohoku Medical Megabank is supported by grants from the Reconstruction Agency, from the Ministry of Education, Culture, Sports, Science, and Technology, and from the Japan Agency for Medical Research and Development. (JP20km0105001). The authors sincerely express their gratitude to the people of Japan and the world for their valuable support to the Great East Japan Earthquake-affected areas after the disaster. We also thank all participants and all municipality staffs who helped our project. We also thank the members of Tohoku University Tohoku Medical Megabank Organization (ToMMo) and Iwate Medical University Iwate Tohoku Medical Megabank Organization (IMM), including Genome Medical Research Coordinators, office and administrative personnel, and software engineers, for their assistance to the project. The complete list of members is available at https://www.megabank.tohoku.ac.jp/english/a181201/ for ToMMo and at http://iwate-megabank.org/en/about/departments/ for IMM.
Publisher Copyright:
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2021/12
Y1 - 2021/12
N2 - Background: We determined the prevalence of current cigarette smokers and alcohol drinkers among cancer survivors and subjects with no history of cancer in Japan and compared the findings with nationally representative studies in other countries. Methods: We conducted a cross-sectional study of baseline data from a prospective cohort study. A self-administered questionnaire was surveyed during 2013–2015 with residents aged ≥20 years attending a community-based cardiometabolic screening program in Miyagi prefecture in north-eastern Japan. Subjects with past cancer histories were classified as cancer survivors. Sex-specific, age-standardized prevalence of current smokers, and drinkers were calculated. Age-adjusted prevalence ratios (PRs: the cancer survivors’ rate divided by the rate of subjects with no history of cancer) and 95% confidence intervals (CIs) were estimated with log-binomial regressions. Results: 36,786 subjects, including 2760 cancer survivors, responded and provided usable information (58.9% of recruited subjects). For men, the age-standardized prevalence of current smokers and drinkers among survivors was 18.8% and 74.4%, respectively, with an age-adjusted PR (95%CI) of 0.76 (0.66–0.86, p < 0.001) and 0.95 (0.91–0.98, p = 0.002), respectively. For women, the figures were 6.1%, 37.9%, 0.84 (0.67–1.06, p = 0.138) and 0.96 (0.90–1.03, p = 0.313), respectively. The U.S., the U.K, and Australian studies generally showed no substantially lower prevalence of current smokers or drinkers in survivors than in subjects with no history of cancer (PR ≥ 0.75), while Korean studies did (PR < 0.75). Conclusions: A considerable proportion of Japanese cancer survivors, especially men, remained currently smoking and drinking. Consistent with Western studies, the rates were not substantially lower than those among subjects with no history of cancer.
AB - Background: We determined the prevalence of current cigarette smokers and alcohol drinkers among cancer survivors and subjects with no history of cancer in Japan and compared the findings with nationally representative studies in other countries. Methods: We conducted a cross-sectional study of baseline data from a prospective cohort study. A self-administered questionnaire was surveyed during 2013–2015 with residents aged ≥20 years attending a community-based cardiometabolic screening program in Miyagi prefecture in north-eastern Japan. Subjects with past cancer histories were classified as cancer survivors. Sex-specific, age-standardized prevalence of current smokers, and drinkers were calculated. Age-adjusted prevalence ratios (PRs: the cancer survivors’ rate divided by the rate of subjects with no history of cancer) and 95% confidence intervals (CIs) were estimated with log-binomial regressions. Results: 36,786 subjects, including 2760 cancer survivors, responded and provided usable information (58.9% of recruited subjects). For men, the age-standardized prevalence of current smokers and drinkers among survivors was 18.8% and 74.4%, respectively, with an age-adjusted PR (95%CI) of 0.76 (0.66–0.86, p < 0.001) and 0.95 (0.91–0.98, p = 0.002), respectively. For women, the figures were 6.1%, 37.9%, 0.84 (0.67–1.06, p = 0.138) and 0.96 (0.90–1.03, p = 0.313), respectively. The U.S., the U.K, and Australian studies generally showed no substantially lower prevalence of current smokers or drinkers in survivors than in subjects with no history of cancer (PR ≥ 0.75), while Korean studies did (PR < 0.75). Conclusions: A considerable proportion of Japanese cancer survivors, especially men, remained currently smoking and drinking. Consistent with Western studies, the rates were not substantially lower than those among subjects with no history of cancer.
KW - Japan
KW - alcohol drinking
KW - cancer survivor
KW - cross-sectional study
KW - prevalence
KW - smoking
UR - http://www.scopus.com/inward/record.url?scp=85120325187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120325187&partnerID=8YFLogxK
U2 - 10.1002/cam4.4364
DO - 10.1002/cam4.4364
M3 - Article
C2 - 34850586
AN - SCOPUS:85120325187
SN - 2045-7634
VL - 10
SP - 9000
EP - 9011
JO - Cancer Medicine
JF - Cancer Medicine
IS - 24
ER -